Published in Int J Radiat Oncol Biol Phys on January 29, 2010
Correlation of (18)F-FDG avid volumes on pre-radiation therapy and post-radiation therapy FDG PET scans in recurrent lung cancer. Int J Radiat Oncol Biol Phys (2014) 2.01
Baseline ¹⁸F-FDG PET image-derived parameters for therapy response prediction in oesophageal cancer. Eur J Nucl Med Mol Imaging (2011) 1.81
PET-guided delineation of radiation therapy treatment volumes: a survey of image segmentation techniques. Eur J Nucl Med Mol Imaging (2010) 1.60
Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology. Eur J Nucl Med Mol Imaging (2011) 1.58
PET functional volume delineation: a robustness and repeatability study. Eur J Nucl Med Mol Imaging (2011) 1.41
Robustness of intratumour ¹⁸F-FDG PET uptake heterogeneity quantification for therapy response prediction in oesophageal carcinoma. Eur J Nucl Med Mol Imaging (2013) 1.33
Temporal analysis of intratumoral metabolic heterogeneity characterized by textural features in cervical cancer. Eur J Nucl Med Mol Imaging (2013) 1.26
Impact of tumor size and tracer uptake heterogeneity in (18)F-FDG PET and CT non-small cell lung cancer tumor delineation. J Nucl Med (2011) 1.25
Assessment of tumour size in PET/CT lung cancer studies: PET- and CT-based methods compared to pathology. EJNMMI Res (2012) 1.15
Computer-aided diagnosis systems for lung cancer: challenges and methodologies. Int J Biomed Imaging (2013) 1.14
Characterization of PET/CT images using texture analysis: the past, the present… any future? Eur J Nucl Med Mol Imaging (2016) 1.07
Impact of partial-volume effect correction on the predictive and prognostic value of baseline 18F-FDG PET images in esophageal cancer. J Nucl Med (2012) 1.04
An approach to identify, from DCE MRI, significant subvolumes of tumors related to outcomes in advanced head-and-neck cancer. Med Phys (2012) 1.02
Volumetric CT-based segmentation of NSCLC using 3D-Slicer. Sci Rep (2013) 0.98
A semiautomatic CT-based ensemble segmentation of lung tumors: comparison with oncologists' delineations and with the surgical specimen. Radiother Oncol (2012) 0.96
A review on segmentation of positron emission tomography images. Comput Biol Med (2014) 0.94
Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer? Eur J Nucl Med Mol Imaging (2015) 0.92
Optimal co-segmentation of tumor in PET-CT images with context information. IEEE Trans Med Imaging (2013) 0.89
Early prediction of pathological response in locally advanced rectal cancer based on sequential 18F-FDG PET. Acta Oncol (2012) 0.87
Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer. Eur J Nucl Med Mol Imaging (2012) 0.87
Development of a nomogram combining clinical staging with (18)F-FDG PET/CT image features in non-small-cell lung cancer stage I-III. Eur J Nucl Med Mol Imaging (2016) 0.86
FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy. Eur J Nucl Med Mol Imaging (2016) 0.86
Functional and molecular image guidance in radiotherapy treatment planning optimization. Semin Radiat Oncol (2011) 0.85
Semiautomatic methods for segmentation of the proliferative tumour volume on sequential FLT PET/CT images in head and neck carcinomas and their relation to clinical outcome. Eur J Nucl Med Mol Imaging (2013) 0.84
Delineation of FDG-PET tumors from heterogeneous background using spectral clustering. Eur J Radiol (2012) 0.83
Challenges and opportunities in patient-specific, motion-managed and PET/CT-guided radiation therapy of lung cancer: review and perspective. Clin Transl Med (2012) 0.82
Spatially resolved regression analysis of pre-treatment FDG, FLT and Cu-ATSM PET from post-treatment FDG PET: an exploratory study. Radiother Oncol (2012) 0.81
(18)F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer. Eur J Nucl Med Mol Imaging (2016) 0.80
Automatic Segmentation of Lung Carcinoma Using 3D Texture Features in 18-FDG PET/CT. Int J Mol Imaging (2013) 0.80
Pathology-based validation of FDG PET segmentation tools for volume assessment of lymph node metastases from head and neck cancer. Eur J Nucl Med Mol Imaging (2013) 0.80
Reliability of PET/CT shape and heterogeneity features in functional and morphological components of Non-Small Cell Lung Cancer tumors: a repeatability analysis in a prospective multi-center cohort. J Nucl Med (2016) 0.80
PETSTEP: Generation of synthetic PET lesions for fast evaluation of segmentation methods. Phys Med (2015) 0.79
The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease. Blood (2014) 0.79
Robust Intratumor Partitioning to Identify High-Risk Subregions in Lung Cancer: A Pilot Study. Int J Radiat Oncol Biol Phys (2016) 0.79
Comparative methods for PET image segmentation in pharyngolaryngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging (2012) 0.77
Functional imaging for radiotherapy treatment planning: current status and future directions-a review. Br J Radiol (2015) 0.77
Optimal definition of biological tumor volume using positron emission tomography in an animal model. EJNMMI Res (2015) 0.76
The evolving role of response-adapted PET imaging in Hodgkin lymphoma. Ther Adv Hematol (2016) 0.75
A method for comparing intra-tumoural radioactivity uptake heterogeneity in preclinical positron emission tomography studies. EJNMMI Phys (2015) 0.75
A novel phantom technique for evaluating the performance of PET auto-segmentation methods in delineating heterogeneous and irregular lesions. EJNMMI Phys (2015) 0.75
A segmentation framework towards automatic generation of boost subvolumes for FDG-PET tumors: a digital phantom study. Eur J Radiol (2012) 0.75
(18)F-FDG PET/CT imaging in rectal cancer: relationship with the RAS mutational status. Br J Radiol (2016) 0.75
Hybrid positron emission tomography segmentation of heterogeneous lung tumors using 3D Slicer: improved GrowCut algorithm with threshold initialization. J Med Imaging (Bellingham) (2017) 0.75
Towards a standard for the evaluation of PET Auto-Segmentation methods: requirements and implementation. Med Phys (2017) 0.75
Impact of consensus contours from multiple PET segmentation methods on the accuracy of functional volume delineation. Eur J Nucl Med Mol Imaging (2015) 0.75
Proton therapy in clinical practice: current clinical evidence. J Clin Oncol (2007) 5.31
Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med (2011) 3.66
Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer (2012) 3.56
The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J Clin Invest (2009) 3.01
Radiomics: the process and the challenges. Magn Reson Imaging (2012) 2.65
Reproducibility of tumor uptake heterogeneity characterization through textural feature analysis in 18F-FDG PET. J Nucl Med (2012) 2.65
Tailoring the atomic structure of graphene nanoribbons by scanning tunnelling microscope lithography. Nat Nanotechnol (2008) 2.49
Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO J (2006) 2.41
Predicting outcomes in radiation oncology--multifactorial decision support systems. Nat Rev Clin Oncol (2012) 2.23
A fuzzy locally adaptive Bayesian segmentation approach for volume determination in PET. IEEE Trans Med Imaging (2009) 2.22
PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys (2007) 2.21
Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol (2009) 2.21
Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol (2012) 2.15
Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol (2013) 2.11
Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med (2008) 2.08
Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol (2004) 1.94
Baseline ¹⁸F-FDG PET image-derived parameters for therapy response prediction in oesophageal cancer. Eur J Nucl Med Mol Imaging (2011) 1.81
The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer (2007) 1.76
Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol (2006) 1.69
Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer. J Thorac Oncol (2012) 1.68
Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys (2009) 1.67
Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer. J Nucl Med (2013) 1.67
Stability of FDG-PET Radiomics features: an integrated analysis of test-retest and inter-observer variability. Acta Oncol (2013) 1.62
Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother Oncol (2009) 1.59
Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology. Eur J Nucl Med Mol Imaging (2011) 1.58
Reproducibility of 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET tumor volume measurements. J Nucl Med (2010) 1.55
Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol (2011) 1.54
A literature review of electronic portal imaging for radiotherapy dosimetry. Radiother Oncol (2008) 1.53
Radiation-induced bullous pemphigoid: a systematic review of an unusual radiation side effect. Radiother Oncol (2006) 1.51
Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer. Radiother Oncol (2008) 1.51
Lysine 63-polyubiquitination guards against translesion synthesis-induced mutations. PLoS Genet (2006) 1.50
Rationale for individualized therapy in Sinonasal Teratocarcinosarcoma (SNTC): case report. Onkologie (2005) 1.48
Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J Nucl Med (2008) 1.44
Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. J Clin Oncol (2010) 1.44
PET functional volume delineation: a robustness and repeatability study. Eur J Nucl Med Mol Imaging (2011) 1.41
The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer. Radiother Oncol (2010) 1.40
Geant4-based Monte Carlo simulations on GPU for medical applications. Phys Med Biol (2013) 1.39
[White paper on radiation oncology in France. Twelve proposals to improve a major cancer treatment. Société française de radiothérapie oncologique]. Cancer Radiother (2013) 1.39
Automated Delineation of Lung Tumors from CT Images Using a Single Click Ensemble Segmentation Approach. Pattern Recognit (2013) 1.36
The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning. Cancer Treat Rev (2006) 1.35
Intra-patient variability of tumor volume and tumor motion during conventionally fractionated radiotherapy for locally advanced non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys (2006) 1.34
Biomarkers for radiation-induced small bowel epithelial damage: an emerging role for plasma Citrulline. World J Gastroenterol (2007) 1.34
Robustness of intratumour ¹⁸F-FDG PET uptake heterogeneity quantification for therapy response prediction in oesophageal carcinoma. Eur J Nucl Med Mol Imaging (2013) 1.33
Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. Int J Radiat Oncol Biol Phys (2003) 1.32
Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol (2012) 1.31
Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res Ther (2006) 1.30
Platelet function in sepsis. Crit Care Med (2002) 1.29
Impact of tumor size and tracer uptake heterogeneity in (18)F-FDG PET and CT non-small cell lung cancer tumor delineation. J Nucl Med (2011) 1.25
Inducers of immunogenic cancer cell death. Cytokine Growth Factor Rev (2013) 1.24
Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys (2005) 1.24
Citrulline: a physiologic marker enabling quantitation and monitoring of epithelial radiation-induced small bowel damage. Int J Radiat Oncol Biol Phys (2003) 1.24
Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys (2010) 1.23
Establishment of a Radiogenomics Consortium. Int J Radiat Oncol Biol Phys (2010) 1.23
Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.22
A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancer. Radiother Oncol (2007) 1.22
The hypoxic proteome is influenced by gene-specific changes in mRNA translation. Radiother Oncol (2005) 1.22
A pathology-based substrate for target definition in radiosurgery of brain metastases. Int J Radiat Oncol Biol Phys (2006) 1.22
Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer. J Nucl Med (2012) 1.21
Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study. Int J Radiat Oncol Biol Phys (2005) 1.18
Dose-response relationships within the parotid gland after radiotherapy for head and neck cancer. Radiother Oncol (2004) 1.17
Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother Oncol (2011) 1.15
Accurate prediction of pathological rectal tumor response after two weeks of preoperative radiochemotherapy using (18)F-fluorodeoxyglucose-positron emission tomography-computed tomography imaging. Int J Radiat Oncol Biol Phys (2009) 1.15
Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation. Lung Cancer (2011) 1.15
How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons. Radiother Oncol (2010) 1.15
Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration: a comparison with sugar permeability tests. Cancer (2005) 1.14
Plasma citrulline concentration: a surrogate end point for radiation-induced mucosal atrophy of the small bowel. A feasibility study in 23 patients. Int J Radiat Oncol Biol Phys (2004) 1.13
Tumour delineation and cumulative dose computation in radiotherapy based on deformable registration of respiratory correlated CT images of lung cancer patients. Radiother Oncol (2007) 1.13
Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Cancer Treat Rev (2007) 1.12